Expression of CD68 and Fas Ligand in Colon Mucosa of Patients with Inflammatory Bowel Disease as Prognostic Markers of Cancerogenesis
- Authors: Santimov A.V1, Kolobov A.V2, Karev V.E3, Kolobova O.L1, Kostik M.M1, Dubko M.F1, Kalashnikova O.V1, Masalova V.V1, Snegireva L.S1, Volkova N.L1, Khvatov A.A1, Belogurova M.B1, Chasnyk V.G1
-
Affiliations:
- St Petersburg State Pediatric Medical University
- Saint Petersburg State University
- Research Institute of Children Infection Diseases FMBA of Russia
- Issue: Vol 7, No 3 (2016)
- Pages: 42-48
- Section: Articles
- URL: https://journals.rcsi.science/pediatr/article/view/5722
- DOI: https://doi.org/10.17816/PED7342-48
- ID: 5722
Cite item
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Andrey V Santimov
St Petersburg State Pediatric Medical University
Author for correspondence.
Email: a.santimoff@gmail.com
MD, Research Fellow, Department of Hospital Pediatrics Russian Federation
Andrey V Kolobov
Saint Petersburg State University
Email: pathandrey@rambler.ru
MD, PhD, Associate Professor, Department of Pathology Russian Federation
Vadim E Karev
Research Institute of Children Infection Diseases FMBA of Russia
Email: karev@fromru.com
MD, PhD, Head of the Lab of Pathomorphology Russian Federation
Oksana L Kolobova
St Petersburg State Pediatric Medical University
Email: aksjutakolobova@rambler.ru
MD, PhD, Associate Professor, Department of Hospital Pediatrics Russian Federation
Mikhail M Kostik
St Petersburg State Pediatric Medical University
Email: kost-mikhail@yandex.ru
MD, PhD, Associate Professor, Department of Hospital Pediatrics Russian Federation
Margarita F Dubko
St Petersburg State Pediatric Medical University
Email: mf-dubko@yandex.ru
MD, PhD, Associate Professor, Department of Hospital Pediatrics Russian Federation
Olga V Kalashnikova
St Petersburg State Pediatric Medical University
Email: koira7@yandex.ru
MD, PhD, Associate Professor, Department of Hospital Pediatrics Russian Federation
Vera V Masalova
St Petersburg State Pediatric Medical University
Email: masalova.vera@gmail.com
Assistant Professor, Department of Hospital Pediatrics Russian Federation
Lyudmila S Snegireva
St Petersburg State Pediatric Medical University
Email: l.s.snegireva@mail.ru
MD, Department of Pediatrics No 3 Russian Federation
Natalia L Volkova
St Petersburg State Pediatric Medical University
Email: volkovanatalia.dr@yandex.ru
MD, Head of Department. Department of Gastroenterology Russian Federation
Andrey A Khvatov
St Petersburg State Pediatric Medical University
Email: andrey_hvatov@mail.ru
Assistant Professor, Department of Oncology. Russian Federation
Margarita B Belogurova
St Petersburg State Pediatric Medical University
Email: deton.hospital31@inbox.ru
MD, PhD, Dr Med Sci, Professor, Head of the Department of Oncology Russian Federation
Vyacheslav G Chasnyk
St Petersburg State Pediatric Medical University
Email: chasnyk@gmail.com
MD, PhD, Dr Med Sci, Professor, Head of the Department of Hospital Pediatrics Russian Federation
References
- Залетова Н.К., Чухловин А.Б., Третьяк А.Т., и др. Генетические факторы, влияющие на эффективность терапии глюкокортикоидами при хронических воспалительных заболеваниях кишечника у детей // Педиатр. — 2015. — Т. 4. — № 3. — С. 91–97. [Zaletova NK, Chukhlovin A B, Tretjak AT, et al. Genetic factors modifying response to glucocorticoid treatment in chronic pediatric inflammatory bowel diseases. Pediatr (St Petersburg). 2015;4(3):91-97 (In Russ).]
- Маркова Д.О., Ревнова М.О., Насыров Р.А. Цитомегаловирусная инфекция у больных с воспалительными заболеваниями кишечника // Педиатр. — 2013. — Т. 4. — № 1. — С. 95–99. [Markova DO, Revnova MO, Nasyrov RA. Cytomegalovirus infection in the patients with in FLammatory bowel disease. Pediatr (St Petersburg). 2013;4 (1):95-99. (In Russ).].
- Allen C, Hogg N. Elevation of infiltrating mononuclear phagocytes in human colorectal tumors. J Natl Cancer Inst. 1987 Mar;78(3):465-70.
- Askling J, Dickman PW, Karlén P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001 May;120(6):1356-62. doi: 10.1053/gast.2001.24052.
- Bell S, Kamm MA. Antibodies to tumour necrosis factor alpha as treatment for Crohn’s disease. Lancet. 2000 Mar 11;355(9207):858-60. doi: 10.1016/S0140-6736(99)00442-0.
- Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002 Mar;196(3):254-65. doi: 10.1002/path.1027.
- Chaput N, Svrcek M, Aupérin A, et al. Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer. Br J Cancer. 2013 Aug 20;109(4):1013-22. doi: 10.1038/bjc.2013.362. Epub 2013 Jul 18.
- Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn’s disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut. 1994; 35:950-4. doi: 10.1136/gut.35.7.950.
- Crohn B, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci. 1925;170:220-8. doi: 10.1097/00000441-192508010-00006.
- Demetter P, De Vos M, Van Huysse JA, et al. Colon mucosa of patients both with spondyloarthritis and Crohn’s disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis. 2005 Feb;64(2): 321-4. Epub 2004 May 27. doi: 10.1136/ard.2003.018382.
- Di Sabatino A, Ciccocioppo R, Luinetti O, et al. Increased enterocyte apoptosis in inflamed areas of Crohn’s disease. Dis Colon Rectum. 2003 Nov;46(11):1498-507. doi: 10.1007/s10350-004-6802-z.
- Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcera- tive colitis: a meta-analysis. Gut. 2001;48:526-35. doi: 10.1136/gut.48.4.526.
- Ekbom A, Helmick C, Zack M, Adami H. Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet. 1990;336:357-9. doi: 10.1016/0140-6736(90)91889-I.
- Holness CL, Simmons DL. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood. 1993 Mar 15;81(6):1607-13.
- Liu S, Russo PA, Baldassano RN, Sullivan KE. CD68 expression is markedly different in Crohn’s disease and the colitis associated with chronic granulomatous disease. Inflamm Bowel Dis. 2009 Aug;15(8):1213-7. doi: 10.1002/ibd. 20890.
- Nagata S, Golstein P. The Fas death factor. Science. 1995 Mar 10;267(5203):1449-56. doi: 10.1126/science.7533326.
- O’Connell J, Bennett MW, O’Sullivan GC, et al. The Fas counterattack: cancer as a site of immune privilege. Immunol Today. 1999 Jan; 20(1):46-52. doi: 10.1016/S0167-5699(98)01382-6.
- Odze RD. Pathology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am. 2006;35:533. doi: 10.1016/j.gtc.2006.07.007.
- Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 1984 Dec 20-1985 Jan 2;312(5996):724-9.
- Pohl C, Hombach A, Kruis W. Chronic inflammatory bowel disease and cancer. Hepatogastroenterology. 2000 Jan-Feb;47(31):57-70.
- Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004 Jan;4(1):71-8. doi: 10.1038/nrc1256.
- Shih DQ, Targan SR. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol. 2008 Jan 21;14(3):390-400. doi: 10.3748/wjg. 14.390.
- Thyberg J, Graf W, Klingenström P. Intestinal fine structure in Crohn’s disease. Lysosomal inclusions in epithelial cells and macrophages. Virchows Arch A Pathol Anat Histol. 1981;391(2):141-52. doi: 10.1007/BF00437592.
- Ueyama H, Kiyohara T, Sawada N, et al. High Fas ligand expression on lymphocytes in lesions of ulcerative colitis. Gut. 1998 Jul;43(1):48-55. doi: 10.1136/gut.43.1.48.
- Weedon DD, Shorter RG, Ilstrup DM, et al. Crohn’s disease and cancer. N Engl J Med. 1973 Nov 22;289(21):1099-103. doi: 10.1056/NEJM197311222892101.
- Zhang W, Ding EX, Wang Q, et al. Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege. World J Gastroenterol. 2005 Jun 21;11(23):3632-5. doi: 10.3748/wjg.v11.i23.3632.
- Zhang Y, Sime W, Juhas M, Sjölander A. Crosstalk between colon cancer cells and macrophages via inflammatory mediators and CD47 promotes tumour cell migration. Eur J Cancer. 2013 Oct;49(15):3320-34. doi: 10.1016/j.ejca.2013.06.005. Epub 2013